Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin FamilyMatthew A. Gregory, Barrie Wilkinson, Michael Bobardt et al.|Antimicrobial Agents and Chemotherapy|2011Cited by 54
Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to AlisporivirJose A. Garcia-Rivera, Philippe Gallay, Barrie Wilkinson et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 42
Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral InfectionMagnus J. Hansson, Matthew A. Gregory, Steven J. Moss et al.|Chemistry & Biology|2015Cited by 38
Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infectionSteven J. Moss, Matthew A. Gregory, Michael Bobardt et al.|MedChemComm|2011Cited by 26
Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver FibrosisSonia Serrano, Ramin Massoumi, Alvar Grönberg et al.|Cells|2019Cited by 21